Incyte Gears Up to Report Q3 Earnings Heres What You Should Know
| SNDX Stock | USD 10.81 0.16 1.50% |
Slightly above 50% of Syndax Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Syndax Pharmaceuticals stock suggests that some investors are interested at this time. Syndax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syndax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
INCYs third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Read at finance.yahoo.com
 |
Syndax Pharmaceuticals Fundamental Analysis
We analyze Syndax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Syndax Pharmaceuticals is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Syndax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Syndax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Syndax Pharmaceuticals Related Equities
| MRSN | Mersana Therapeutics | 11.43 | ||||
| STRO | Sutro Biopharma | 7.14 | ||||
| REPL | Replimune | 3.55 | ||||
| DYN | Dyne Therapeutics | 1.19 | ||||
| KROS | Keros Therapeutics | 0.85 | ||||
| CGEM | Cullinan Oncology | 0.25 | ||||
| INZY | Inozyme Pharma | 0.25 | ||||
| RVMD | Revolution Medicines | 0.15 | ||||
| VRDN | Viridian Therapeutics | 0.07 | ||||
| PCVX | Vaxcyte | 0.06 | ||||
| COGT | Cogent Biosciences | 0.60 | ||||
| MLYS | Mineralys Therapeutics, | 2.04 | ||||
| CYTK | Cytokinetics | 2.62 | ||||
| PLRX | Pliant Therapeutics | 2.92 | ||||
| MRUS | Merus BV | 3.73 | ||||
| KALV | Kalvista Pharmaceuticals | 3.79 | ||||
| EWTX | Edgewise Therapeutics | 3.91 | ||||
| LRMR | Larimar Therapeutics | 6.31 |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.